Document is current
Any future updates will be listed below
-
Authors
Balkwill, Frances R. https://orcid.org/0000-0002-5587-9759
Laumont, Céline M. https://orcid.org/0000-0002-9067-4054
Burdett, Nikki
Le Saux, Olivia
Garsed, Dale W. https://orcid.org/0000-0003-1223-0121
Grither, Whitney R.
Nijhuis, Anke M.
Recouvreux, Maria S.
Kang, Ziqi https://orcid.org/0009-0003-2084-610X
Zhang, Rugang https://orcid.org/0000-0002-7255-2360
Chiappinelli, Katherine B.
Lee, Jason S. https://orcid.org/0000-0003-0879-934X
Laniti, Denarda Dangaj https://orcid.org/0000-0002-5659-6427
McNeish, Iain https://orcid.org/0000-0002-9387-7586
Ahmed, Ahmed A. https://orcid.org/0000-0001-6509-2581
Rottapel, Robert
Conejo-Garcia, Jose R. https://orcid.org/0000-0001-6431-4074
Odunsi, Kunle
Pharoah, Paul D. P. https://orcid.org/0000-0001-8494-732X
Zamarin, Dmitriy https://orcid.org/0000-0002-0094-0161
Ishak, Charles A.
Fotopoulou, Christina
Buckanovich, Ronald J.
Labidi-Galy, Intidhar
Brenton, James D. https://orcid.org/0000-0002-5738-6683
Lengyel, Ernst https://orcid.org/0000-0001-8624-1507
Cook, David P.
George, Sophia H. L. https://orcid.org/0000-0003-1013-1883
Lheureux, Stephanie
Drapkin, Ronny https://orcid.org/0000-0002-6912-6977
Nephew, Kenneth P.
Adams, Sarah https://orcid.org/0000-0002-0240-1380
Pathania, Shailja
Nelson, Brad H. https://orcid.org/0000-0002-4445-5539
Färkkilä, Anniina
Fuh, Katherine
Neel, Benjamin G. https://orcid.org/0000-0002-9589-585X
Bowtell, David D.
- License Information
-
More Information
Article History
Accepted: 23 February 2026
First Online: 13 April 2026
Competing interests
: J.D.B. is a shareholder in Tailor Bio. A.A.A. is a founder, director, and consultant for Singular Bio Ltd. S.H.L.G. receives research grants from Pfizer, Advenchen, and GSK. K.O. is a co-founder of Tactiva Therapeutics. D.Z. reports institutional grants from Merck, Genentech, AstraZeneca, Xencor, Zymeworks, and Synthekine; personal fees from AstraZeneca, Xencor, Memgen, Daichi Sankyo, Gilead, Synthekine, Immunos, Hervolution, Accurius, Replimune, and Calidi Biotherapeutics; and holds a patent on the use of oncolytic Newcastle Disease Virus for cancer therapy. K.B.C. reports consulting fees from ROME Therapeutics and Daiichi Sankyo, and has a sponsored research agreement with Enara Bio. J.R.C.-G. receives consulting fees from Alloy Therapeutics and licensing fees from Anixa Biosciences; holds intellectual property with Anixa Biosciences and Compass Therapeutics; and is co-founder of Cellepus Therapeutics, a CAR gamma/delta T cell company. E.L. receives research funding from AbbVie through the University of Chicago to study ovarian cancer. D.D.L. has received research grants from Hoffmann-La Roche AG and 10xGenomics. S.A. receives clinical trial funding from AstraZeneca. F.R.B. receives an honorarium from GSK and research funding from AstraZeneca. D.D.B. has received research grant funding from Hoffmann-La Roche and Astra Zeneca. C.M.L., N.B., O.L.S., D.W.G., W.R.G., A.M.N., M.S.R., Z.K., R.Z., J.S.L., I.M., R.R., P.D.P.P., C.A.I., C.F., R.J.B., I.L.-G., D.P.C., S.L., R.D., K.P.N., S.P., B.H.N., A.F., K.F., and B.G.N. all declare no competing interests.
